Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Instagram Outage Disrupts Thousands of U.S. Users 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Dublin, Oct. 20, 2016 -- Research and Markets has announced the addition of the "The Overview of Japanese Pharmaceutical Industry ver2016" report to their offering.
This report talks about the overview of Japanese pharmaceutical industry. By reading this report, readers will understand overall picture about the industry, from various aspects.
Domestic pharmaceutical market size is said to be about 6.9 trillion yen at the ex-manufacturer level, and about 10.8 trillion yen in terms of drug price. While the market size of non-prescription drugs is slightly declining, that of ethical drugs is on the rise, accounting for about 90% of the whole market.
Key Topics Covered:
1. Summary
2. Definition of pharmaceutical industry
3. Classification of pharmaceutical industry
4. Definition of drugs
5. Distribution structure of drugs
6. Pharmaceutical market size in Japan
7. Regulation of related laws
8. Related industry groups
9. High profitability
10. Long history and family management
11. Difficulty of new drug development
12. Structural risk peculiar to the pharmaceutical industry, Patent cliff
13. Disclosure of pipeline
14. Low penetration of vertical integration
15. Changing business environment
16. Companies striving for structural reform
17. Differences between Japanese and foreign companies
18. Characteristics of Labour market
19. Concentration of major companies in member countries of the Organization for Economic Co-operation and Development (OECD)
20. Reference: Comparison with the U.S. and European countries
For more information about this report visit http://www.researchandmarkets.com/research/k4qjk2/the_overview_of
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Pharmaceuticals
